Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Chinese participants with obesity or overweight
NCT05024032Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05024032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024032.